Novartis Advances First Targeted Therapy for Chronic Inducible Urticaria
BASEL, Switzerland, June 12, 2026 Novartis announced new Phase III data at the European Academy of Allergy and Clinical...
AI drug discovery Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
BASEL, Switzerland, June 12, 2026 Novartis announced new Phase III data at the European Academy of Allergy and Clinical...
BOSTON and SHENZHEN, China, June 10, 2026 XtalPi, a global leader in AI and robotics-driven drug discovery, has announced...
WILMINGTON, Del. & SAN MATEO, Calif., May 20, 2026 Incyte and Genesis Molecular AI have announced a significant expansion...
TOKYO, Japan & CAMBRIDGE, Mass., March 13, 2026 PRISM BioLab Co., Ltd. and Receptor.AI Inc. have announced a strategic...
HONG KONG, Jan. 5, 2026 — Ascletis Pharma Inc. announced that it has received Investigational New Drug (IND) clearance...
SAN MATEO, Calif., October 8, 2025 — Vivace Therapeutics, Inc., a biotechnology company pioneering small molecule cancer therapies that...
